Literature DB >> 15346852

Evaluation of type I error rates when modeling ordered categorical data in NONMEM.

Ulrika Wählby1, Katalin Matolcsi, Mats O Karlsson, E Niclas Jonsson.   

Abstract

The development of non-linear mixed pharmacokinetic/pharmacodynamic models for continuous variables is usually guided by graphical assessment of goodness of fit and statistical significance criteria. The latter is usually the likelihood ratio test (LR). When the variable to be modeled is categorical, on the other hand, the available graphical methods are less informative and/or more complicated to use and the modeler needs to rely more heavily on statistical significance assessment in the model development. The aim of this study was to evaluate the type I error rates, obtained from using the LR test, for inclusion of a false parameter in a non-linear mixed effects model for ordered categorical data when modeling with NONMEM. Data with four ordinal categories were simulated from a logistic model. Two nested multinomial models were fitted to the data, the model used for simulation and a model containing one additional parameter. The difference in fit (objective function value) between models was calculated. Three types of models were explored; (i) a model without interindividual variability (IIV) where the addition of a parameter describing IIV was assessed, (ii) a model with IIV where the addition of a drug effect parameter (either categorical or continuous drug exposure measure) was evaluated, and (iii) a model including IIV and drug effect where the inclusion of a random effects parameter on the drug effect was assessed. Alterations were made to the simulation conditions, for example, varying the number of individuals and the size and distribution of the IIV, to explore potential influences on the type I error rate. The estimated type I error rate for inclusion of a false random effect parameter in model (i) and (iii) were, as expected, lower than the nominal. When the additional parameter was a fixed effects parameter describing drug effect (model(II)) the estimated type I error rates were in agreement with the nominal. None of the different simulation conditions tried changed this pattern. Thus, the LR test seems appropriate for judging the statistical significance of fixed effects parameters when modeling categorical data with NONMEM.

Entities:  

Mesh:

Year:  2004        PMID: 15346852     DOI: 10.1023/b:jopa.0000029489.97168.a9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  12 in total

Review 1.  Modelling ordered categorical data: recent advances and future challenges.

Authors:  A Agresti
Journal:  Stat Med       Date:  1999 Sep 15-30       Impact factor: 2.373

2.  The need for mixed-effects modeling with population dichotomous data.

Authors:  I Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

3.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

4.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

5.  Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.

Authors:  S K Gupta; G Sathyan; E A Lindemulder; P L Ho; L B Sheiner; L Aarons
Journal:  Clin Pharmacol Ther       Date:  1999-06       Impact factor: 6.875

6.  Population pharmacokinetic data and parameter estimation based on their first two statistical moments.

Authors:  S L Beal
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

Review 7.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

8.  Population pharmacodynamic model for ketorolac analgesia.

Authors:  J W Mandema; D R Stanski
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

9.  Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.

Authors:  Diane R Mould; Nicholas H G Holford; Jan H M Schellens; Jos H Beijnen; Paul R Hutson; Hilde Rosing; Willem W ten Bokkel Huinink; Eric K Rowinsky; Joan H Schiller; Mark Russo; Graham Ross
Journal:  Clin Pharmacol Ther       Date:  2002-05       Impact factor: 6.875

10.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data.

Authors:  L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

View more
  4 in total

1.  Design of pharmacokinetic studies for latent covariates.

Authors:  Chakradhar V Lagishetty; Carolyn V Coulter; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-10       Impact factor: 2.745

2.  Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-05       Impact factor: 2.745

3.  Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-06-10       Impact factor: 2.745

4.  Comparisons of Analysis Methods for Proof-of-Concept Trials.

Authors:  K E Karlsson; C Vong; M Bergstrand; E N Jonsson; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.